Trial Profile
A Phase 2 Single-Center, Proof-of-Concept Safety and Efficacy Study of Orally Administered OLT1177 Capsules with Successive, Result-Dependent Dose Adaptation in Subjects with an Acute Gout Flare
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Dapansutrile (Primary)
- Indications Gout
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Olatec Therapeutics
- 27 Oct 2020 According to an Olatec Therapeutics media release, clinical trial data from this study were published in The Lancet Rheumatology.
- 11 May 2020 According to an Olatec Therapeutics Media Release, the company was the main funder of the trial, along with the National Institutes of Health and The Interleukin Foundation.
- 11 May 2020 Results published in the Olatec Therapeutics Media Release.